Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. - Wikidata - wikimedia - TriplyDB

Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin.

Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin.

http://www.wikidata.org/entity/Q43918793

about

Noninvasive Imaging of Nanomedicines and Nanotheranostics: Principles, Progress, and Prospects.Polymer-drug conjugates: origins, progress to date and future directions The big picture on nanomedicine: the state of investigational and approved nanomedicine products Towards a targeted multi-drug delivery approach to improve therapeutic efficacy in breast cancer Improving aqueous solubility and antitumor effects by nanosized gambogic acid-mPEG₂₀₀₀ micelles Clinical Translation of Nanomedicine.Nanoparticles for imaging: top or flop?The Theranostic Path to Personalized Nanomedicine A deeper insight into the postpolymerization modification of polypenta fluorophenyl methacrylates to poly(n-(2-hydroxypropyl) methacrylamide).HPMA copolymer-1,5-diazaanthraquinone conjugates as novel anticancer therapeutics.Targeting angiogenesis-dependent calcified neoplasms using combined polymer therapeutics A phase I study of nedaplatin, pemetrexed and thoracic intensity-modulated radiotherapy for inoperable stage III lung adenocarcinoma Recent trends in targeted anticancer prodrug and conjugate design.Paclitaxel-loaded polymeric micelles modified with MCF-7 cell-specific phage protein: enhanced binding to target cancer cells and increased cytotoxicity.Characterizing EPR-mediated passive drug targeting using contrast-enhanced functional ultrasound imaging HPMA copolymers: origins, early developments, present, and future.Endocytic uptake of a large array of HPMA copolymers: Elucidation into the dependence on the physicochemical characteristics Polymeric nanomedicine for cancer MR imaging and drug delivery Macromolecular therapeutics Sequential combination therapy of ovarian cancer with degradable N-(2-hydroxypropyl)methacrylamide copolymer paclitaxel and gemcitabine conjugates.Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology.Polymer-drug conjugates: recent development in clinical oncology Nanomedical engineering: shaping future nanomedicines.Evaluation of pullulan-functionalized doxorubicin nanoparticles for asialoglycoprotein receptor-mediated uptake in Hep G2 cell line.Protease-activated drug development.Physical and chemical strategies for therapeutic delivery by using polymeric nanoparticles.Can formulation and drug delivery reduce attrition during drug discovery and development-review of feasibility, benefits and challenges.Gene- and immunotherapy for hepatocellular carcinoma.Biological rationale for the design of polymeric anti-cancer nanomedicines.Prostate-cancer-targeted N-(2-hydroxypropyl)methacrylamide copolymer/docetaxel conjugates.Multifunctional synthetic poly(L-glutamic acid)-based cancer therapeutic and imaging agents.Targeting Cathepsin B for Cancer Therapies.Lactosylated liposomes for targeted delivery of doxorubicin to hepatocellular carcinoma.Mannosylated lipid nano-emulsions loaded with lycorine-oleic acid ionic complex for tumor cell-specific delivery.Cathepsin B-cleavable doxorubicin prodrugs for targeted cancer therapy (Review)A phase I study with MAG-camptothecin intravenously administered weekly for 3 weeks in a 4-week cycle in adult patients with solid tumours Tumour-targeted nanomedicines: principles and practice.Anticancer carrier-linked prodrugs in clinical trials.Alternate routes for drug delivery to the cell interior: pathways to the Golgi apparatus and endoplasmic reticulum Cellular distribution of injected PLGA-nanoparticles in the liver.

P2860

Q26822871-F22F71BE-1859-43AA-8AC3-357075B32FC0 Q27002505-1C42F1FB-EEE8-42A1-B390-BA0AFF286BB2 Q27021817-EC7DAD31-A9AC-4F7D-BF83-D16633055C85 Q28291499-E4B2DC9F-D517-485B-8455-083296807318 Q28660830-7901F818-8C9B-437D-9B01-1F083A8F56ED Q30355939-9D4D1ACE-9677-472C-80CF-1C103C7E1C10 Q30429119-78A9E76F-3698-464A-B584-04BFD357373E Q30437998-A6D7D1FA-04BC-4265-A162-96184E77205E Q30834120-A43923EE-87CF-4881-B9A7-607BC5D4EED3 Q30979368-B6C9E3D2-FEF9-4ED2-9E23-03BC7765E013 Q33432776-C5445132-FBB4-4798-BF31-48BA9DB81CDB Q33435839-07C89CB8-FE0C-45EC-942D-CD89FDD44EA5 Q33573762-61ED3B5D-51CB-437E-A050-E55285F982C3 Q33592506-3B2CA468-8A04-4149-9027-5F81508C753C Q33651804-52436254-B639-40DE-B5A2-9E73B78ED059 Q33719148-49C57518-5D0F-4889-A8D0-C5CE96E30491 Q33732592-310428CB-5B37-4381-9FE1-8CEB92B5F079 Q33773418-670F2897-A067-4012-86AF-C983BB4F5B57 Q34079574-83C6B04B-BBBE-4914-B872-36316BB1E731 Q34082844-9581CA5F-7FED-4A4C-A414-FA0BEB236DB7 Q34447986-CDBF4851-C719-4A38-825C-65947EEDCBF8 Q34656003-60286BD8-B75B-4FA7-9924-2EC162CECE9D Q35019550-0639E4DF-1218-4B11-842F-348BFE296E8E Q35673292-9CD47CF9-ACBD-4C2C-8E3F-235AD1A7DA02 Q35811508-9DAA5EA8-2BFA-48B9-B694-51547DC450A3 Q36105465-B3EB2DD0-3354-4613-B489-0177D245F028 Q36111924-DBE615E4-4E0B-4BB7-84FE-2EA8C078B92B Q36150432-D7551CBE-B5C2-4F68-8536-67241A6B12A5 Q36160333-B66CD5B7-68A2-4BBA-A901-1F065487787E Q36160805-3E316548-582F-4AB6-B8F4-9623F80CB740 Q36214907-714F3D2D-54DE-48B0-A938-61EE1B5BE6A5 Q36326605-CD865F02-4616-40F2-AB3D-72F5DF27D6CA Q36334145-CC5CBE31-DED4-4155-8361-566662689DC3 Q36452190-98AA61E3-0BF4-4144-8B93-D9AA30D96691 Q36643541-70E12AAB-68AF-426D-8FDB-EF6867EF1E78 Q36694292-01BD13C5-BF39-4CF3-BEEC-0BD3BF84BF0F Q36858135-6EDF4717-B5A9-4AED-BF65-5C4F0C1FB058 Q36861603-BA3625BD-4396-4237-B560-7313E5C4AE2A Q36899294-8C68E57C-1B9C-427E-BB66-8FF7F8BDB939 Q36957725-7CADAC50-ECD1-4022-8731-8BE81212ED2A

P2860

Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin.

http://www.wikidata.org/entity/Q43918793

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh-hant

name

Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin.

@en

Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin.

@nl

type

label

Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin.

@en

Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin.

@nl

prefLabel

Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin.

@en

Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin.

@nl

P1433

Q43918793-04B41118-566B-40B5-A631-D93DF6404285

P1476

Q43918793-A6EAE7E8-5D0D-4459-981E-BD6A216A5680

P2093

Q43918793-08338E5A-455D-4EC9-AA9D-6B6A63A72289

Q43918793-09E5634C-E459-4920-92EA-84CF6C036169

Q43918793-39CF3179-394F-4D67-B819-1F41BC5ADEC0

Q43918793-516F0D94-53B7-427A-B382-F40D6EF6BE2D

Q43918793-60BB09D6-3512-46F5-A293-D494AFE4A708

Q43918793-65EDD856-AE4E-44AC-8FDA-04517A46C195

Q43918793-8C084714-C646-409E-A1CB-A78E0CA88530

Q43918793-AE609A26-B4C1-49AC-8C91-5F37FD008A3A

Q43918793-B3840E76-6A98-40F9-88AE-7180AFD375F6

Q43918793-B7596CDA-4E05-43FC-9655-B0B270AC28E8

P304

Q43918793-09E0200F-C8B6-4956-BACA-1FA65EA0DCC9

P31

Q43918793-98DE174C-D358-4D79-ADF0-73133B68AB2E

P356

Q43918793-4CFCC6D0-DE46-4931-AFBE-86483419423D

P407

Q43918793-886DC9F0-25CA-4FFF-AAA6-9552661863E2

P433

Q43918793-E9003635-9525-46E7-AC0F-5595B75AC585

P478

Q43918793-589FF2BB-DDC8-451D-B132-99B120621268

P577

Q43918793-A4884B26-EA73-4915-AB8D-450D85A76D32

P698

Q43918793-C893829E-29DC-4146-8342-402224C4A852

P356

P1433

Journal of Clinical Oncology

P1476

Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin.

@en

P2093

Annie M Young

http://www.w3.org/2001/XMLSchema#string

Cancer Research Campaign Phase I/II Clinical Trials committee

http://www.w3.org/2001/XMLSchema#string

David Anderson

http://www.w3.org/2001/XMLSchema#string

David J Kerr

http://www.w3.org/2001/XMLSchema#string

David R Ferry

http://www.w3.org/2001/XMLSchema#string

Jayne Doran

http://www.w3.org/2001/XMLSchema#string

Leonard W Seymour

http://www.w3.org/2001/XMLSchema#string

Peter J Julyan

http://www.w3.org/2001/XMLSchema#string

Richard Poyner

http://www.w3.org/2001/XMLSchema#string

Sally Burtles

http://www.w3.org/2001/XMLSchema#string

P304

1668-1676

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.20.6.1668

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P577

2002-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11896118

http://www.w3.org/2001/XMLSchema#string